Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology

被引:23
作者
Li, Lei [1 ]
Zhao, Xiuli
Yang, Chunrong [2 ]
Hu, Haiyang
Qiao, Mingxi
Chen, Dawei
机构
[1] Shenyang Pharmaceut Univ, Dept Pharmaceut, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China
[2] Jiamusi Univ, Coll Pharm, Jiamusi, Peoples R China
关键词
Optimization; central composite design; response surface methodology; albumin nanoparticles; desolvation; doxorubicin; PROCESS PARAMETERS; DELIVERY-SYSTEM; DRUG-DELIVERY; NANOSPHERES; FORMULATION; RATS; PH;
D O I
10.3109/03639045.2011.563781
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The objective of this work was to optimize the preparation of doxorubicin-loaded albumin nanoparticles (Dox-A-Nps) through desolvation procedures using response surface methodology (RSM). A central composite design (CCD) for four factors at five levels was used in this study. Method: Albumin nanoparticles were prepared through a desolvation method and were optimized in the aid of CCD. Albumin concentration, amount of doxorubicin, pH values, and percentage of glutaraldehyde were selected as independent variables, particle size, zeta potential, drug loading, encapsulation efficiency, and nanoparticles yield were chosen as response variables. RSM and multiple response optimizations utilizing a quadratic polynomial equation were used to obtain an optimal formulation. Results: The optimal formulation for Dox-A-Nps was composed of albumin concentration of 17 mg/ml, amount of doxorubicin of 2 mg/ml, pH value is 9 and percentage of glutaraldehyde of 125% of the theoretic amount, under which the optimized conditions gave rise to the actual average value of mean particle size (151 +/- 0.43 nm), zeta potential (-18.8 +/- 0.21 mV), drug loading efficiency (21.4 +/- 0.70%), drug entrapment efficiency (76.9 +/- 0.21%) and nanoparticles yield (82.0 +/- 0.34%). The storage stability experiments proved that Dox-A-Nps stable in 4 degrees C over the period of 4 months. The in vitro experiments showed a burst release at the initial stage and followed by a prolonged release of Dox from albumin nanoparticles up to 60 h. Conclusions: This study showed that the RSM-CCD method could efficiently be applied for the modeling of nanoparticles, which laid the foundation of the further research of immuno nanoparticles.
引用
收藏
页码:1170 / 1180
页数:11
相关论文
共 44 条
[1]  
Armstrong NA., 1990, Understanding Experimental Designs and Interpretation in Pharmaceutics
[2]   Kinetic constants determination for an alkaline protease from Bacillus mojavensis using response surface methodology [J].
Beg, QK ;
Saxena, RK ;
Gupta, R .
BIOTECHNOLOGY AND BIOENGINEERING, 2002, 78 (03) :289-295
[3]   The effect of mixed-solvent and Terpenes on percutaneous absorption of meloxicam gel [J].
Chang, Jui-Sheng ;
Tsai, Yi-Hung ;
Wu, Pao-Chu ;
Huang, Yaw-Bin .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (09) :984-989
[4]   Therapeutic nanoparticles for drug delivery in cancer [J].
Cho, Kwangjae ;
Wang, Xu ;
Nie, Shuming ;
Chen, Zhuo ;
Shin, Dong M. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1310-1316
[5]   DOXORUBICIN-LOADED NANOSPHERES BYPASS TUMOR-CELL MULTIDRUG RESISTANCE [J].
CUVIER, C ;
ROBLOTTREUPEL, L ;
MILLOT, JM ;
LIZARD, G ;
CHEVILLARD, S ;
MANFAIT, M ;
COUVREUR, P ;
POUPON, MF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (03) :509-517
[6]   Buccal bioadhesive delivery system of 5-fluorouracil: Optimization and characterization [J].
Dhiman, Munish Kumar ;
Yedurkar, Pramod D. ;
Sawant, Krutika K. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2008, 34 (07) :761-770
[7]   Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes [J].
Dinauer, N ;
Balthasar, S ;
Weber, C ;
Kreuter, J ;
Langer, K ;
von Briesen, H .
BIOMATERIALS, 2005, 26 (29) :5898-5906
[8]   ANALYSIS OF ALBUMIN MICROSPHERE PREPARATION [J].
GALLO, JM ;
HUNG, CT ;
PERRIER, DG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1984, 22 (01) :63-74
[9]   Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma [J].
Gelperina, SE ;
Khalansky, AS ;
Skidan, IN ;
Smirnova, ZS ;
Bobruskin, AI ;
Severin, SE ;
Turowski, B ;
Zanella, FE ;
Kreuter, J .
TOXICOLOGY LETTERS, 2002, 126 (02) :131-141
[10]   Nanoparticles for drug delivery in cancer treatment [J].
Haley, Barbara ;
Frenkel, Eugene .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (01) :57-64